Söndag 24 November | 22:52:10 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-11-05 09:00 Kvartalsrapport 2025-Q3
2025-08-05 09:00 Kvartalsrapport 2025-Q2
2025-05-08 09:00 Kvartalsrapport 2025-Q1
2025-02-14 09:00 Bokslutskommuniké 2024
2024-11-05 - Kvartalsrapport 2024-Q3
2024-09-17 - Split CRBX 100:1
2024-08-06 - Kvartalsrapport 2024-Q2
2024-05-07 - Kvartalsrapport 2024-Q1
2024-04-29 - X-dag ordinarie utdelning CRBX 0.00 SEK
2024-04-26 - Årsstämma
2024-02-16 - Bokslutskommuniké 2023
2024-01-10 - Extra Bolagsstämma 2024
2023-11-07 - Kvartalsrapport 2023-Q3
2023-08-08 - Kvartalsrapport 2023-Q2
2023-05-09 - Kvartalsrapport 2023-Q1
2023-04-24 - X-dag ordinarie utdelning CRBX 0.00 SEK
2023-04-21 - Årsstämma
2023-02-17 - Bokslutskommuniké 2022
2022-11-08 - Kvartalsrapport 2022-Q3
2022-08-09 - Kvartalsrapport 2022-Q2
2022-05-10 - Kvartalsrapport 2022-Q1
2022-04-25 - X-dag ordinarie utdelning CRBX 0.00 SEK
2022-04-22 - Årsstämma
2022-02-18 - Bokslutskommuniké 2021
2021-11-09 - Kvartalsrapport 2021-Q3
2021-08-10 - Kvartalsrapport 2021-Q2
2021-05-11 - Kvartalsrapport 2021-Q1
2021-04-26 - X-dag ordinarie utdelning CRBX 0.00 SEK
2021-04-23 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-11-10 - Kvartalsrapport 2020-Q3
2020-08-11 - Kvartalsrapport 2020-Q2
2020-05-12 - Kvartalsrapport 2020-Q1
2020-04-27 - X-dag ordinarie utdelning CRBX 0.00 SEK
2020-04-24 - Årsstämma
2020-02-12 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriLäkemedel & Handel
Carbiotix är ett bioteknikföretag inom upcycling av växtbaserade sidoströmmar på plats. Carbiotix mission är att förbättra människors hälsa genom att öka konsumtionen av prebiotika och andra aktiva ingredienser från återvunna sidoströmmar. Carbiotix erbjuder en upcycling- och berikningstjänst på plats som gör det möjligt för bolag att förvandla växtbaserade produkter till funkionella produkter. Bolaget grundades under 2014 och har sitt huvudkontor i Lund.
2024-03-12 16:00:00

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the Company's first ever animal-related LinkGut service order from a leading company developing microbiome intervention solutions for different human and animal applications. This test order relates to samples taken from canines and is valued at 32,000 SEK. This is the first time that Carbiotix has offered its LinkGut microbiome diagnostic service for animal related applications. This development increases the potential customer base for the LinkGut service, now including both human and animal applications.

Erik Deaner, CEO of Carbiotix, comments:
"I am very pleased to announce that Carbiotix has ventured into the animal microbiome diagnostics market with the first LinkGut service order for an animal application. Although the value of this first test order is only 32,000 SEK, it is symbolic and demonstrates the viability and appeal of the LinkGut service for animal related applications. Even though animals are not our core business, the flexibility of our LinkGut service offer makes it attractive for areas other than human applications. This includes animals trained for special purposes, such as K-9s, companion animals such as dogs and cats, animals involved in husbandry activities, as well as wild animals being researched.

As with human applications, customers studying animals are looking for a microbiome service provider that can provide value with regards to cost, flexibility and reliability. We will continue to market our leadership position across all three of these areas and continue to explore new opportunities in the over 2 Billion Euro market for microbiome sequencing services (1 (https://www.expertmarketresearch.com/reports/microbiome-sequencing-services-market)).

This development also has the potential to assist Carbiotix to begin selling its prebiotic modulators for animal food related applications like pet food, as well as investigating potential upcycling opportunities with pet food and animal husbandry companies through the NutraCycle service.

This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company's contact person set out below on 12 March 2024.

Forward-looking statements
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.

For further information:
Carbiotix AB
Erik Deaner, CEO
Tel: +46 (0)738 67 30 85
E-mail: erik.deaner@carbiotix.com

Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a portfolio of prebiotic modulators and diagnostic testing services